Practices
Capital Markets
Captial Markets: Recent Follow-on Offerings
Since 2009, we have been involved in 450+ public offerings including some of the nation's most notable securities transactions. Following are some recent representative offerings.
Completed Follow-on Offerings
- Underwriters in Reata Pharmaceuticals $115.9 million Follow-On (July 2017)
- Regulus Therapeutics $46.0 million Follow-On (July 2017)
- Apollo Endosurgery $31.3 million Follow-On (July 2017)
- Inovio Pharmaceuticals $75.0 million Follow-On (July 2017)
- CymaBay Therapeutics $97.2 million Follow-On (July 2017)
- Alder Biopharmaceuticals $172.5 million Follow-On (July 2017)
- Arena Pharmaceuticals $150.0 million Follow-On (July 2017)
- Underwriters in Egalet Corporation $30.0 million Follow-On (July 2017)
- Minerva Neurosciences $41.8 million Follow-On (June 2017)
- AveXis $287.5 million Follow-On (June 2017)
- Underwriters in Pacific Biosciences of California $47.8 million Follow-On (June 2017)
- Underwriters in Savara $42.9 million Follow-On (June 2017)
- Senseonics $41.0 million Follow-On (May 2017)
- GlycoMimetics $92.6 million Follow-On (May 2017)
- Syndax Pharmaceuticals $49.7 million Follow-On (May 2017)
- Underwriters in MINDBODY $141.4 million Follow-On (May 2017)
- ZioPharm Oncology in its $50.0 million Follow-On (May 2017)
- Underwriters in Arbor Realty Trust $77.9 million Follow-On (May 2017)
- Underwriters in Accelerate Diagnostics $79.4 million Follow-On (May 2017)
- Cytokinetics in its $75.0 million Follow-On (May 2017)
- Underwriters in Ignyta $88.4 million Follow-On (May 2017)
- Underwriters in AGNC Investment Corp. $507.2 million Follow-On (May 2017)
- Underwriters in TransEnterix $24.9 million Follow-On (April 2017)
- Underwriters in Karyopharm Therapeutics $40.0 million Follow-On (April 2017)
- Underwriters in Audentes Therapeutics $86.3 million Follow-On (April 2017)
- Arena Pharmaceuticals $79.4 million Follow-On (April 2017)
- Underwriters in Wave Life Sciences $100.0 million Follow-On (April 2017)
- Axovant $143.7 million Follow-On (April 2017)
- FibroGen $120.0 million Follow-On (April 2017)
- Everbridge $73.8 million Follow-On (April 2017)
- Cara Therapeutics $92.1 million Follow-On (March 2017)
- Underwriters in CytoSorbents $9.99 million Follow-On (March 2017)
- Biocept $9.3 million Follow-On (March 2017)
- Underwriters in Vital Therapies, Inc. $40.3 million Follow-On (March 2017)
- Underwriters in Heat Biologics Inc.$4.0 million Follow-On (March 2017)
- Bellicum Pharmaceuticals, Inc. in its $69.0 million Follow-On (March 2017)
- Calithera Biosciences, Inc. in its $80.5 million Follow-On (March 2017)
- Underwriters in Intrepid Potash, Inc. $60.4 million Follow-On (March 2017)
- Underwriters in Anthera Pharmaceuticals, Inc. $15.0 million Follow-On (March 2017)
- Aurinia Pharmaceuticals Inc. in its $173.1 million Follow-On (March 2017)
- Underwriters in Ooma, Inc. $29.1 million Follow-On (March 2017)
- Kite Pharma, Inc. in its $409.7 million Follow-On (March 2017)
- Underwriters in Dermira, Inc. $193.8 million Follow-On (March 2017)
- Underwriters in Global Blood Therapeutics $143.8 million Follow-On (February 2017)
- Helius Medical Technologies in its $9.5 million Follow-On (February 2017)
- Underwriters in Sierra Oncology $29.5 million Follow-On (February 2017)
- CymaBay Therapeutics, Inc. in its $10.0 million Follow-On (February 2017)
- Rigel Pharmaceuticals, Inc. in its $46.0 million Follow-On (January 2017)
- Mirati Therapeutics, Inc. in its $68.7 million Follow-On (January 2017)
- Arena Pharmaceuticals Inc. in its $50.0 million Follow-On (January 2017)
- Aurinia Pharmaceuticals Inc. in its $28.8 million Follow-On (December 2016)
- Clearside Biomedical, Inc. in its $41.4 million Follow-On (December 2016)
- Xencor in its $126.5 million Follow-On (November 2016)
- TRACON Pharmaceuticals, Inc. in its $17.4 million Follow-On (November 2016)
- Aclaris Therapeutics, Inc. in its $91.0 million Follow-On (November 2016)
- AmpliPhi Biosciences Corporation in its $4.0 million Follow-On (November 2016)
- Underwriters in Invitae Corporation $43.9 million Follow-On (November 2016)
- Flexion Therapeutics in its $64.8 million Follow-On (November 2016)
- Underwriters in HealthEquity, Inc. $89.6 million Follow-On (October 2016)
- Sunesis Pharmaceuticals, Inc. $19.0 million Follow-On (October 2016)
- Underwriters in Ascendis Pharma Inc. $136.4 million Follow-On (October 2016)
- Underwriters in Nektar Therapeutics in $201.8 million Follow-On (October 2016)
- Biocept Inc. in its $10.0 million Follow-On (October 2016)
- Cidara Therapeutics, Inc. in its $25.0 million Follow-On (October 2016)
- Versartis, Inc. in its $63.4 million Follow-On (September 2016)
- Enphase Energy, Inc. in its $15.6 million Follow-On (September 2016)
- Aquinox Pharmaceuticals Inc. in its $65.5 million Follow-On (September 2016)
- Immune Design Corp. in its $32.7 million Follow-On (September 2016)
- Underwriters in Xenon Pharmaceuticals Inc. $30.0 million Follow-On (September 2016)
- AveXis Inc. in its $168.8 million Follow-On (September 2016)
- Sophiris Bio in its $29.9 million Follow-On (August 2016)
- Eiger BioPharmaceuticals in its $20 million Follow-On (August 2016)
- Underwriters in Recro Pharma $14.9 million Follow-On (August 2016)
- Immunocellular Therapeutics in its $7.5 million Follow-On (August 2016)
- Acadia Pharmaceuticals Inc. in its $200.0 million Follow-On (August 2016)
- BioMarin Pharmaceutical Inc. in its $720.0 million Follow-On (August 2016)
- Paratek Pharmaceuticals, Inc. in its $55.3 million Follow-On (June 2016)
- Scynexis Inc. in its $22.5 million Follow-On (June 2016)
- GlycoMimetics, Inc. in its $20.1 million Follow-On (June 2016)
- Minerva Neurosciences, Inc. in its $57.5 million Follow-On (June 2016)
- Underwriters in Dermira Inc. $144.9 million Follow-On (June 2016)
- Flexion Therapeutics, Inc. in its $77.0 million Follow-On (June 2016)
- AmpliPhi Biosciences Corporation in its $5.0 million Follow-On (May 2016)
- Sophiris Bio, Inc. in its $5.0 million Follow-On (May 2016)
- Biocept Inc. in its $5.0 million Follow-On (April 2016)
- Underwriters in Ignyta, Inc. $57.5 million Follow-On (April 2016)
- Underwriters in Durect Corporation $17.2 million Follow-On (April 2016)
- Alder Biopharmaceuticals, Inc. in its $143.8 million Follow-On (April 2016)
- Underwriters in Vitae Pharmaceuticals, Inc. $40.0 million Follow-On (March 2016)
- Underwriters in Energy Fuels Inc. $12.1 million Follow-On (March 2016)
- Adamas Pharmaceuticals in its $61.8 million Follow-On (January 2016)
- Underwriters in Prothena Corporation plc $119.3 million Follow-On (January 2016)
- Underwriters in Epizyme, Inc. $138.0 million Follow-On (January 2016)
- Underwriters in Otonomy, Inc. $115.0 million Follow-On (January 2016)
- Acadia Pharmaceuticals in its $300.0 million Follow-On (January 2016)